Depression in HIV occurs commonly and causes poor HIV outcomes with public health implications.
Depression prevalence in HIV-infected persons is estimated at 26% compared to 5% in the general population. Adherence to antiretroviral medication is a life-saving treatment in HIV, but depression can reduce engagement in care and adherence to medication. Depression is also associated with poorer levels of viral suppression and even mortality. Overall, those with depression and HIV are less likely to return to health and remain more likely to transmit the virus. therefore, treatment of HIV is essential to prevention; lower engagement in and adherence to HIV treatment due to depression puts others at risk. This is a 3 part trial, an initial pilot, a placebo controlled pilot, and a full trial.
Part 1. Dose response, Tolerability/Acceptability of Metformin for Depression in people with HIV: To do Initial assessment of metformin for depression in people with HIV we will perform a randomized, double blind, 2-arm, 12 week randomized controlled trial to assess feasibility and acceptability of metformin for depression. We will test two doses of metformin 1000 mg daily versus 1500 mg daily.
Part 2. Preliminary Efficacy Trial of Metformin for Depression in People with HIV: This will be a two-arm, double-blind trial of metformin versus placebo in people with HIV and depression. We will randomize individuals 1:1 to metformin or placebo. Will then collect blood and rectal swabs for preliminary assessments of the mechanism of action for metformin in people with HIV and depression.
Part 3. Full efficacy factorial trial of metformin for depression and comparison/interaction with fluoxetine in people living with HIV: To assess metformin and fluoxetine as efficacious treatments for depression in people with HIV, we will conduct a 4-arm, 12-week, mechanistic, double-blinded, randomized controlled treatment trial (RCT) with an assessment of inflammation and the gut microbiome. Participants (n=400) will be HIV- positive patients on ART with comorbid depression receiving care at one of two Ugandan clinics. In addition, we will use the NIMH Research Domain Criteria (RDoC) of Acute Threat and loss under Negative Valence using biomarkers and self-reported tools.

开始日期2026-01-01

申办/合作机构

University of Minnesota

TCTR20240817009

/ Not yet recruiting临床1期

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin 50/1000 mg Film-coated Tablets and Reference Product (GALVUS MET (50 MG/1000 MG)) in Healthy Thai Volunteers under Fed Conditions

开始日期2025-02-06

申办/合作机构-

IRCT20220111053692N19

/ CompletedN/A

Bioequivalence study of Metformin ER ??? mg Tablet (Tehran chemie) versus Glucophage® XR ??? mg (Merck-Brand) Tablet after single oral dosing in healthy volunteers

开始日期2024-12-30

申办/合作机构

Tehran Chemie Pharmaceutical Co.

100 项与二甲双胍相关的临床结果

登录后查看更多信息

100 项与二甲双胍相关的转化医学

登录后查看更多信息

100 项与二甲双胍相关的专利（医药）

登录后查看更多信息

43,674

项与二甲双胍相关的文献（医药）

2025-12-31·Gut Microbes

Microbial succinate promotes the response to metformin by upregulating secretory immunoglobulin a in intestinal immunity

Article

作者: Wang, Aiting ; Liu, Bing ; Zhang, Yu ; Qin, Jia’an ; Yan, Dan ; Yao, Chengcheng ; Yuan, Mingxia ; Zhao, Wei ; Long, Jianglan ; Zhang, Ying

Metformin is the first-line pharmacotherapy for type 2 diabetes mellitus; however, many patients respond poorly to this drug in clinical practice. The potential involvement of microbiota-mediated intestinal immunity and related signals in metformin responsiveness has not been previously investigated. In this study, we successfully constructed a humanized mouse model by fecal transplantation of the gut microbiota from clinical metformin-treated - responders and non-responders, and reproduced the difference in clinical phenotypes of responsiveness to metformin. The abundance of Bacteroides thetaiotaomicron, considered a representative differential bacterium of metformin responsiveness, and the level of secretory immunoglobulin A (SIgA) in intestinal immunity increased significantly in responder recipient mice following metformin treatment. In contrast, no significant alterations in B. thetaiotaomicron and SIgA were observed in non-responder recipient mice. The study of IgA^-/- mice confirmed that downregulated expression or deficiency of SIgA resulted in non-response to metformin, meaning that metformin was unable to improve dysfunctional glucose metabolism and reduce intestinal and adipose tissue inflammation, ultimately leading to systemic insulin resistance. Furthermore, supplementation with succinate, a microbial product of B. thetaiotaomicron, potentially reversed the non-response to metformin by inducing the production of SIgA. In conclusion, we demonstrated that upregulated SIgA, which could be regulated by succinate, was functionally involved in metformin response through its influence on immune cell-mediated inflammation and insulin resistance. Conversely, an inability to regulate SIgA may result in a lack of response to metformin.

2025-12-31·ANNALS OF MEDICINE

Improvement of endocrine and metabolic conditions in patients with polycystic ovary syndrome through acupuncture and its combined therapies: a systematic review and meta-analysis

Review

作者: Hu, Jinqun ; Yang, Jie ; Kong, Fanjing ; Wu, Tianyu ; Liu, Yiwei ; Liu, Yu ; Chen, Jiao

BACKGROUND:

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder among women of reproductive age that significantly impacts their reproductive health. Acupuncture and its combined therapies may have beneficial effects on the endocrine and metabolic states of women with PCOS. This systematic review and meta-analysis evaluated the treatment effects and potential mechanisms of acupuncture and its combined therapies compared to oral metformin in treating PCOS patients.

METHODS:

The evaluation focused on three sets of outcomes: hormonal indicators, metabolic indicators, and body weight indicators. Studies that involved additional therapies beyond the specified interventions or included patients with other diseases were excluded. Additionally, data mining methods were used, including frequency statistics to analyze the frequency of acupuncture points and the meridians involved, and the Apriori algorithm to perform association rule analysis for the most effective interventions.

RESULTS:

The study included 46 articles (51 studies) involving six interventions: acupuncture combined with metformin, acupuncture treatment, acupuncture with Chinese herbal medicine and metformin, acupuncture with Chinese herbal medicine, acupuncture combined with cupping, and auricular acupuncture combined with metformin showed significant improvements in all evaluated indicators. Data mining revealed the Stomach meridian of foot yangming was the most frequently used, and the most commonly used combination of points included CV4, SP6, and ST36.

CONCLUSIONS:

This study suggests that acupuncture and its combined therapies may benefit PCOS. However, risk of bias and heterogeneity observed were noted. Future high-quality, rigorously designed randomized controlled trials are needed to confirm these findings and provide stronger clinical recommendations for acupuncture in PCOS treatment.

2025-12-31·ANNALS OF MEDICINE

Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis

Review

作者: Qiu, Kaijie ; Wang, Jie ; Wang, Haibiao ; Gan, Yichao ; Jiang, Keting ; Zhou, Songsheng ; Wang, Donghuan

BACKGROUND:

Numerous meta-analyses have identified various risk factors for hepatocellular carcinoma (HCC), prompting a comprehensive study to synthesize evidence quality and strength.

METHODS:

This umbrella review of meta-analyses was conducted throughout PubMed, EMBASE, Web of Science, and Cochrane Database of Systematic Reviews. Evidence strength was evaluated according to the evidence categories criteria.

RESULTS:

We identified 101 risk factors throughout 175 meta-analyses. 31 risk factors were classified as evidence levels of class I, II, or III. HBV and HCV infections increase HCC risk by 12.5-fold and 11.2-fold, respectively. These risks are moderated by antiviral treatments and virological responses but are exacerbated by higher HBsAg levels, anti-HBc positivity, and co-infection. Smoking, obesity, non-alcoholic fatty liver disease, diabetes, low platelet, elevated liver enzymes and liver fluke infection increase HCC risk, while coffee consumption, a healthy diet, and bariatric surgery lower it. Medications like metformin, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), aspirin, statins, and selective serotonin reuptake inhibitors reduce HCC risk, while acid suppressive agents, particularly proton pump inhibitors, elevate it. Blood type O reduces the risk of HCC, while male gender and older age increase the risk.

CONCLUSIONS:

HBV and HCV are major HCC risk factors, with risk mitigation through antiviral treatments. Lifestyle habits such as smoking and alcohol use significantly increase HCC risk, highlighting the importance of cessation. Certain drugs like aspirin, statins, GLP-1 RAs, and metformin may reduce HCC occurrence, but further research is needed to confirm these effects.

1,389

项与二甲双胍相关的新闻（医药）

2025-06-05

·梅斯医学

OCC 2025 | 陈明龙教授：数字医疗在房颤整合管理中的应用

房颤（AF）作为一种复杂的慢性疾病，需要多维度管理。在全球范围内，房颤患者人群呈现显著多样性，同时医疗资源分布不均的问题普遍存在，这使得为所有患者提供规范化治疗面临巨大挑战。近期，第十九届东方心脏病学会议（OCC 2025）在上海圆满召开。来自江苏省人民医院的陈明龙教授以 “数字医疗在房颤整合管理中的应用” 为题进行专题报告，系统阐述了数字技术如何突破传统医疗边界，为房颤全周期管理提供创新解决方案。本文结合会议精华内容，梳理关键进展与实践路径，以期为临床同道提供参考。房颤（AF）作为一种复杂的慢性疾病，需要多维度管理。在全球范围内，房颤患者人群呈现显著多样性，同时医疗资源分布不均的问题普遍存在，这使得为所有患者提供规范化治疗面临巨大挑战。近期，第十九届东方心脏病学会议（OCC 2025）在上海圆满召开。来自江苏省人民医院的陈明龙教授以 “数字医疗在房颤整合管理中的应用” 为题进行专题报告，系统阐述了数字技术如何突破传统医疗边界，为房颤全周期管理提供创新解决方案。本文结合会议精华内容，梳理关键进展与实践路径，以期为临床同道提供参考。数字健康是指数字技术在医疗健康领域的使用。数字化房颤整合管理的研究大多是观察性研究，研究样本量小，随访时间短，无法收集到足够数量的结局事件，导致无法检验出统计学差异。许多研究缺乏对照组，并侧重于前后变化，易受到霍桑效应的影响。此外，RCT研究多为整群设计，因此患者的基线资料和用药方案常具有显著差异，同时，选择方法偏差可能会影响研究结果。数字医疗在房颤整合管理中的应用可归纳为以下五大类：（一）数字医疗强化的房颤管理以 mAFA 研究为代表，该研究评估了移动技术支持下的房颤筛查及整合管理模型。干预措施包括基于智能穿戴设备的房颤筛查、ABC 路径（A：抗凝 / 避免卒中；B：更好的症状管理；C：心血管风险因素控制）指导的综合管理，以及远程医疗支持。研究结果显示，干预组患者的缺血性脑卒中 / 系统栓塞、再住院及全因死亡复合终点事件发生率显著降低，抗凝药使用依从性提升，出血风险降低，同时患者的生活质量及房颤认知水平均有显著改善。此外，成本效益分析表明，该管理模式具有潜在的经济学优势。具体而言，基于移动健康的房颤整合管理的成本效益比为每个质量调整生命年14936美元，低于意愿支付的标准(每个质量调整生命年33438美元），提示基于移动健康的房颤整合管理具有潜在的成本效益优势。中国农村老年心房颤动患者的综合管理新模式MIRACLE-AF研究，将江苏省扬州市江都区的30个村卫生室按照1:1的比例分为新型综合管理模式(干预组)和常规管理模式(对照组)，并比较新型综合管理模式的有效性及安全性。结果显示，整合管理提高房颤标准化路径管理依从性(41.8% vs 10.3% 3年），整合管理心血管不良事件相对风险度下降36%。相关成果在2024 欧洲心脏病学年会(ESC)重磅临床试验Hotline发布。本研究特别突出了村医的核心作用，村医是农村最可及的医疗资源，本研究的创新模式赋能村医在房颤管理中发挥主导作用。此外，充分利用了现代科技手段，结合远程医疗平台，让村医获得房颤专家的远程支持，提升农村地区老年房颤患者的管理质量，弥补农村地区医疗资源不足的局限性。（二）远程房颤管理系统emPOWERD - AF研究探讨了myAlgos的可用性， myAlgos是一个移动健康管理系统，由医生端平台与患者端智能手机应用程序组成，旨在通过远程监测与干预优化房颤管理。尽管在6个月随访中，对照组与完整应用程序组的房颤住院数量无显著差异，但干预组患者的生活质量评分呈现改善趋势。另一项针对571例房颤患者的事后分析（TIM-HF2研究）显示，基于远程管理（每日监测体重、血压、心率、心律等指标）可降低因心血管疾病非计划住院的风险（OR 0.60, 95% CI 0.25-0.95），尽管全因死亡风险的降低未达到统计学显著水平。（三）基于数字医疗的心律监测移动心律监测设备（如AliveCor Kardia）在房颤患者中的应用研究显示，可显著改善患者的生活质量评分及日常活动能力，并提升用药依从性。（四）基于数字医疗的患者自我管理和用药依从性工具基于网络平台的整合管理工具）通过房颤教育、用药提醒、症状记录及远程问诊等功能，可显著改善患者的压力应对能力、用药依从性及生活质量，并降低24个月内的再入院风险。这类工具通过赋能患者自我管理，弥补了传统随访模式的不足，尤其适用于慢性病管理需求。（五）临床决策支持系统临床决策支持系统通过优化抗凝方案，可降低治疗方案的不一致性（由63% 降至59%, p=0.02），提升指南依从性（由70%升至73%, p=0.013），并减少大出血事件发生率（1.2% vs 1.6%, p=0.04）。此类系统通过整合循证医学证据与患者个体数据，为临床医生提供实时决策支持，有助于推动房颤治疗的标准化与精准化。尽管数字医疗在房颤管理中展现出显著潜力，但现有研究仍存在以下局限性：研究设计缺陷：多数研究为观察性研究，样本量较小且随访时间短，难以收集足够的结局事件以检验统计学差异；部分 RCT 研究采用整群设计，导致患者基线资料与用药方案存在显著异质性，可能引入选择偏倚。霍桑效应影响：缺乏对照组的前后变化研究易受患者行为改变（霍桑效应）的干扰，影响结果的客观性。实施层面障碍：患者与卫生服务提供者的数字素养差异可能导致技术接受度参差不齐；数据隐私与安全问题在远程医疗场景中尤为突出；资源匮乏地区面临数字设备可及性与可负担性的双重挑战。综上，数字医疗为房颤整合管理带来了革命性机遇，其在优化治疗依从性、降低并发症风险、提升医疗资源利用效率等方面的价值已在多项研究中得到验证。尽管面临研究证据不足、实施障碍等挑战，但随着技术创新的加速与医疗体系的适应性调整，数字医疗有望成为未来房颤管理的核心支柱。通过持续推动高质量研究、加强跨学科协作及提升服务公平性，我们能够逐步实现 “让指南推荐的治疗策略从理想变为现实” 的目标，为全球房颤患者带来更优的临床结局。撰文 | 梅斯医学编辑 | 木白●大反转！从抗癌到促癌？Nature：功能饮料中这种常见成分，促进血癌生长；但曾因“抗癌”作用登上Cell●重磅！多省发文：坚持公立医院去行政化，缩减行政科室！行政人员不得任院长等职！一省头部医院预算负增长，卫生技术人员减少，咋办● 延寿20岁，二甲双胍太“神”了！最新研究：二甲双胍不仅能将活到90岁的几率提升30％，还能全身性抗衰，让大脑年轻6岁左右版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

2025-06-05

·生物谷

你有强迫症吗？出门就担心没锁门、有洁癖？两项研究：强迫症的背后是30个基因位点和上万个遗传变异在操控

提问：你有没有奇奇怪怪的强迫症？或者你身边的人有没有？比如每次出门前总觉得门没锁好、厨房火没关、窗户没关紧，于是折返回去检查一遍又一遍；再比如忍受不了桌上或是地面上有脏东西，一有头发等掉落就要立刻去收拾干净，不然心里总是不舒服……这些行为听起来是不是很熟悉？没错，这些就是强迫症（OCD）的典型表现。强迫症（Obsessive-Compulsive Disorder, OCD)其实是一种常见的心理健康问题，在全世界范围内，终身患病率为1%～2%，并有近10亿人表现出有不同程度的强迫症症状。它的主要特征是两类反复出现的模式：一是令人焦虑的“强迫思维”（例如对细菌的过度担忧、害怕做错事情等），二是为了缓解这些焦虑而反复进行的“强迫行为”（如不断检查门窗、不停洗手等）。表面看来，这些行为似乎只是注重安全或整洁，但强迫症可不仅仅是个小毛病，有时其会严重影响生活质量，甚至可能导致社交障碍、工作效率低下等一系列问题。那么，这种令人困扰的疾病究竟缘何而起？今天，我们就来一起揭开强迫症遗传之谜，看看科学家们是怎么通过研究找出那些隐藏在基因里的“幕后黑手”。30个基因据点的多基因叛乱近日，《Nature Genetics》杂志上发表的研究论文“Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder”为强迫症的遗传学研究带来了重大突破。这项研究由国际强迫症基金会遗传学协作组（IOCDF-GC）和强迫症协作遗传学协会研究（OCGAS）共同完成，汇集了来自全球的53,660例强迫症病例和2,044,417例对照组的数据。研究人员利用全基因组关联研究（GWAS）技术，对这些数据进行了大规模的分析，最终发现了30个与强迫症相关的独立基因位点。这些位点的发现，不仅为强迫症的遗传基础提供了更清晰的图景，还揭示了强迫症与其他精神障碍之间的潜在联系。图1：与强迫症相关的30个全基因组显著位点，分布在不同染色体上图片来源自[1]在研究中，研究人员采用了多种先进的分析方法，包括基因基础分析、组织和细胞类型富集分析以及遗传相关性分析。他们发现，强迫症的遗传风险与大脑中的某些特定细胞类型密切相关，尤其是海马和皮层的兴奋性神经元，以及含有D1和D2型多巴胺受体的中等棘神经元。这些细胞类型在大脑的神经回路中起着关键作用，而强迫症患者的大脑神经回路往往存在异常。换句话说，这些基因位点的异常可能导致大脑中某些神经细胞的功能失调，从而引发强迫症的症状。图2：强迫症遗传信号在大脑特定细胞类型中显著富集图片来源自[1]此外，研究还发现，强迫症的遗传风险会与其他多种精神障碍共享，如焦虑症、抑郁症、厌食症和图雷特综合征。这意味着，强迫症并非孤立存在，它还会与其他精神障碍“拉帮结派”！这一发现为强迫症的诊断和治疗提供了新的思路，也为未来的研究提供了重要的方向。例如，如果某种药物对抑郁症有效，那么它也可能会对强迫症患者有所帮助，因为这两种疾病可能共享某些遗传风险因素。图3：强迫症与焦虑、抑郁等精神障碍正相关，与克罗恩病等自身免疫性疾病负相关图片来源自[1]罕见但破坏力极强的编码变异除了常见的遗传变异，罕见的有害基因变异同样扮演重要角色。2021年6月，《Nature Neuroscience》杂志上发表了一篇题为“Exome sequencing in obsessive–compulsive disorder reveals a burden of rare damaging coding variants”的研究论文，揭示了罕见有害编码变异在强迫症中的作用。这项研究由多个研究机构合作完成，对1,313例强迫症病例进行了全外显子组测序，包括587个三联体、41个四联体和644个额外的无关病例。这是迄今为止针对强迫症进行的最大规模的全外显子组测序研究，旨在探索罕见有害编码变异对强迫症的影响。图4：研究设计概览图片来源自[2]研究人员采用了基因基础的塌陷分析、LoF（Loss of Function）变异率分析和新生突变（De novo mutations）分析等多种方法。他们发现：在LoF不耐受基因中，强迫症病例携带LoF变异的频率显著高于健康对照组！LoF变异是指那些会导致基因功能丧失的变异，这些变异在强迫症患者中更为常见，这表明它们可能对强迫症的发病机制有重要影响。换句话说，这些基因的异常可能导致大脑中的某些功能失调，从而增加患强迫症的风险。此外，新生突变分析显示，在三联体中，强迫症病例携带预测有害的新生错义突变的频率高于对照组，并且在LoF不耐受基因中，新生LoF突变的频率也显著增加。新生突变是指在患者出生时新出现的基因变异，这些变异不是从父母遗传而来，而是在胚胎发育过程中产生的。这些新生突变在强迫症患者中更为常见，表明它们可能在强迫症的发病中起重要作用。特别值得一提的是，当研究者比较变异频率时，有一个基因——SLITRK5基因，其罕见有害编码变异在强迫症病例中显著增加，引起了研究者的兴趣。SLITRK5 基因在大脑的突触形成中起着重要作用，其功能异常可能导致大脑神经回路的异常，从而增加强迫症的风险。例如，敲除Slitrk5的小鼠表现出增加的焦虑和过度梳理行为，这与人类强迫症患者的行为模式相似。研究者推测，这个基因的变异可能会影响大脑中神经细胞之间的连接，进而导致强迫症的症状。图5：SLITRK5基与强迫症风险相关图片来源自[2]小结这两项突破性研究，如同照亮黑暗的灯塔，为我们揭示了强迫症复杂的遗传图谱及其与其他精神障碍的深层关联。它们不仅深化了我们对强迫症这种疾病根源的理解，更指向了个性化诊疗的崭新可能。所以说，科学的意义不仅在于解释痛苦，更在于赋予希望。如此，终有一日，那些困在痛苦循环中的人们，会等到神经科学带来的解放日~参考文献：[1]Strom NI, Gerring ZF, Galimberti M, et al. Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder. Nat Genet. Published online May 13, 2025. [2]Halvorsen M, Samuels J, Wang Y, et al. Exome sequencing in obsessive-compulsive disorder reveals a burden of rare damaging coding variants. Nat Neurosci. 2021;24(8):1071-1076.撰文｜Shawn编辑 | lcc部分文字来源于网络，本文仅用于分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！精彩推荐：1、年轻是本钱？当心「50岁」就要开始还健康债！两项研究：饮食、活动量、吸烟史、睡眠等8项指标关乎健康长寿，满分者可延寿8.9年2、「猪油」不“罪恶”，是健康的美味！最新发现：与植物油相比，猪油竟在小鼠中显示抗肥潜力，或与其能调节肠道微生物群和胆汁酸代谢有关3、延寿20岁，二甲双胍太“神”了！最新研究：二甲双胍不仅能将活到90岁的几率提升30％，还能全身性抗衰，让大脑年轻6岁左右4、「接吻」竟会传染焦虑？！研究发现：另一半存在抑郁焦虑症状时，另一方的口腔菌群会逐渐“同化”，并伴随焦虑、失眠和激素水平的变化5、你是“恋爱脑”or“完全无恋爱欲望”？最新Cell：性欲由大脑钙通道控制！其能精准调控异性社交兴趣和行为，有显著性别与状态依赖性点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯~

2025-06-05

·GlobeNewswire-Health Care

Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty

As a member of Medicines for Europe, Polpharma Group joins industry leaders in calling on EU Prime Ministers to adopt a 5-Point Pharmaceutical Action Plan to protect patients, boost manufacturing, and ensure fair competitionAMSTERDAM, June 05, 2025 (GLOBE NEWSWIRE) -- Polpharma Group, a leading European pharmaceutical manufacturer, has joined fellow members of Medicines for Europe in signing an open letter addressed to the Prime Ministers and Ministers of Health of all 27 EU Member States. The letter calls for urgent political action to adopt a targeted Pharmaceutical Action Plan that will protect patient access to medicines and support a competitive, sustainable pharmaceutical industry in Europe. The letter, signed by CEOs and senior executives from across the European off-patent medicines sector, focuses on the need to: 1. Accelerate the adoption of the EU pharmaceutical legislation, with a strong emphasis on: Maintaining the current 11-year regulatory exclusivity period to avoid unnecessary healthcare costs.Strengthening and harmonizing the Bolar exemption, enabling generic and biosimilar medicines to enter the market immediately after patent expiry, ensuring faster access for patients and savings for healthcare systems. The threat of U.S. tariffs should not justify extending Europe's intellectual property (IP) protection, which is already the most generous in the world. Any IP extensions would strain public health budgets and fail to prevent production shifts abroad, as already announced by several originator companies. The letter also stresses that EU countries spent €20 billion on just 5 top medicines in 2024. The simulation, based on the originator extension claims (13 to 18 years), for only 15 molecules shows that the costs for healthcare budgets would be between €20 billion and €100 billion. 2. Avoid harmful legislative overlaps, such as those in the Urban Wastewater Treatment Directive (UWWTD), which—if not amended—could unintentionally disrupt medicine supply and increase costs for patients. For example, in the Netherlands alone, the cost of diabetes medicine metformin is expected to increase by up to 875%, and the antibiotic amoxicillin up to 400%. 3. Support critical medicines production, through initiatives like the Critical Medicines Act (CMA), which should be aligned with industrial and health security goals. 98% of on-patent investment is going to the US, while only 1% is going to the EU.Markus Sieger, CEO of Polpharma Group, commented:“Europe must act now to protect its patients and its pharmaceutical sovereignty. The off-patent industry is investing in Europe, but we also need a stable, competitive, and innovation-friendly environment to continue doing so. The 5-Point Action Plan is a pragmatic and urgent roadmap to ensure that essential medicines remain accessible, affordable, and manufactured in Europe.”Polpharma Group remains committed to working with EU institutions and national governments to build a resilient, sustainable, and patient-focused pharmaceutical ecosystem in Europe. Source: Polpharma Group Beata Zduńczyk-Golędzinowska Corporate Communications Head M: +48 693 307 630 beata.zdunczyk-goledzinowska@polpharma.com Grażyna Stachowska Corporate PR Content Expert M: +48 885 610 273 grazyna.stachowska@polpharma.com

100 项与二甲双胍相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	二甲双胍	A10BA02	DB00331

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
分化型甲状腺癌	临床3期	波兰	Medical Research Agency	2022-11-01
缺血性卒中	临床3期	美国	The Medical University of South Carolina	2008-10-01
2型糖尿病	临床3期	美国	National Institute of Diabetes & Digestive & Kidney Diseases	2004-05-01
抑郁症	临床2期	-	University of Minnesota	2026-01-01
HIV感染	临床2期	-	University of Minnesota	2026-01-01
意义不明的单克隆丙种球蛋白病	临床2期	美国	Dana-Farber Cancer Institute, Inc.	2021-04-27
浆细胞白血病	临床2期	美国	Dana-Farber Cancer Institute, Inc.	2021-04-27
阴燃多发性骨髓瘤	临床2期	美国	Dana-Farber Cancer Institute, Inc.	2021-04-27
新型冠状病毒感染	临床阶段不明	美国	University of Minnesota	2022-08-18
枫糖尿病	临床前	美国	Buck Institute for Research on Aging	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02946996 (CTgov)	临床2期	前列腺癌 \| 转移性前列腺癌 \| 前列腺腺癌	41	Metformin (Metformin Only)	膚鹽遞願範範鑰壓廠構(鬱艱鏇鬱積簾糧襯觸選) = 鏇膚選網鹽憲鹽網獵醖範遞醖顧醖範構築範願 (鹽餘獵觸製簾夢衊網窪, 壓憲艱網艱糧顧鏇築製 ~ 網醖選餘獵壓構襯艱壓) 更多	-	2025-02-03
				OPC (OPC Only)	膚鹽遞願範範鑰壓廠構(鬱艱鏇鬱積簾糧襯觸選) = 製構壓齋蓋醖膚網製壓範遞醖顧醖範構築範願 (鹽餘獵觸製簾夢衊網窪, 夢衊範膚糧築繭蓋襯獵 ~ 鬱壓憲選繭蓋壓簾積衊) 更多
WCLC2024 人工标引	N/A	非小细胞肺癌	480	Metformin (Overweight patients)	廠艱繭廠顧憲窪製鏇餘(夢艱蓋膚窪觸顧積遞膚): HR = 0.68 (95% CI, 0.457 ~ 1.011), P-Value = 0.057 更多	积极	2024-09-08
				Metformin (Non-overweight patients)
NCT01107717 (EDICT \| EDICT study, CTgov)	临床4期	2型糖尿病	318	exenatide+pioglitazone+metformin (Triple Therapy)	願選鏇鬱艱獵繭憲範醖(顧艱網襯築顧衊獵襯齋) = 齋醖築觸蓋鹽齋夢窪衊網製餘醖窪遞顧鏇顧膚 (糧糧顧願簾構壓網襯餘, 0.1) 更多	-	2024-09-05
				glargine+metformin+glyburide (Conventional Therapy)	願選鏇鬱艱獵繭憲範醖(顧艱網襯築顧衊獵襯齋) = 遞糧鹹廠構範願網膚觸網製餘醖窪遞顧鏇顧膚 (糧糧顧願簾構壓網襯餘, 0.1) 更多
EULAR2024	N/A	糖尿病前期 serum urate \| CRP	-	Metformin initiators	觸範壓壓廠衊齋構觸獵(選艱顧網鏇廠醖顧製遞) = 餘蓋範齋簾鹹衊憲遞憲選窪膚選積膚壓鹹鹽膚 (鏇鑰夢選艱壓艱積夢顧, 5.1 ~ 10)	积极	2024-06-05
				metformin (Non-users of antidiabetic medication)	觸範壓壓廠衊齋構觸獵(選艱顧網鏇廠醖顧製遞) = 膚鹽壓膚鏇鹹鬱憲醖醖選窪膚選積膚壓鹹鹽膚 (鏇鑰夢選艱壓艱積夢顧, 8.8 ~ 10.2)
ASCO2024	N/A	细胞因子释放综合征 Type 2 diabetes mellitus	237	Metformin	願衊鬱選鏇蓋艱獵窪廠(鑰鹹廠窪範遞衊鹽糧網) = 壓築醖簾淵鑰顧窪憲積選鬱憲觸願蓋遞蓋廠蓋 (繭鏇糧壓窪衊觸醖網醖 ) 更多	积极	2024-05-24
				No Metformin	願衊鬱選鏇蓋艱獵窪廠(鑰鹹廠窪範遞衊鹽糧網) = 鏇齋構夢顧夢齋鑰鹽醖選鬱憲觸願蓋遞蓋廠蓋 (繭鏇糧壓窪衊觸醖網醖 ) 更多
ASCO2024	N/A	转移性结直肠癌 TP53 \| APC \| KRAS ... 更多	-	Metformin+Chemotherapy	觸窪窪獵範築膚鏇憲製(壓壓壓憲繭選鬱淵鹹齋) = 鏇構簾餘齋襯鏇願鹽齋鬱網選構鬱窪廠鹽壓範 (選衊積鏇鑰簾鑰獵獵選 ) 更多	积极	2024-05-24
				Metformin+ICI	觸窪窪獵範築膚鏇憲製(餘夢夢選顧觸醖醖簾鑰) = 夢範積簾網鏇膚選鹹淵窪築艱齋艱顧構夢構蓋 (遞鏇築製繭齋衊衊觸觸 ) 更多
ASCO2024	N/A	HR阳性/HER2阴性乳腺癌 PIK3CAmut	139	Alpelisib 300mg + Fulvestrant 500mg	衊衊製窪築構窪網遞醖(繭遞淵觸襯築醖夢襯獵) = 齋選築衊鏇願觸觸鹹夢鬱選觸築選壓鏇壓窪構 (遞鹹願憲遞鑰獵鏇艱築 ) 更多	积极	2024-05-24
ISN WCN2024	N/A	乳酸性酸中毒	-	Metformin	醖壓簾構艱廠網範鹹選(膚鑰鹹鬱夢齋鏇醖願選) = multiple recurrent electrolyte and divalent ions deficiencies (hypokalemia, hypocalcemia, hypomagnesemia, hypophosphatemia) 鹹鏇範衊艱構網遞壓膚 (廠築網夢醖鬱壓製鹽憲 ) 更多	-	2024-04-01
Tandem Meetings ASTCT and CIBMTR2024	N/A	细胞因子释放综合征 Type 2 diabetes mellitus	237	Metformin	繭觸齋齋範鬱觸製築選(淵範鏇願範艱構網憲繭) = 鏇觸憲築鏇壓鏇遞窪願鏇淵夢遞繭襯鹹鬱壓構 (鏇築網膚繭鏇膚繭獵製 ) 更多	积极	2024-02-01
				No Metformin	繭觸齋齋範鬱觸製築選(淵範鏇願範艱構網憲繭) = 簾蓋獵襯鹹製壓夢鹽艱鏇淵夢遞繭襯鹹鬱壓構 (鏇築網膚繭鏇膚繭獵製 ) 更多